

September 23, 2016

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra East, Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400023

Scrip Code: JUBILANT

Scrip Code: 530019

Dear Sir/Madam,

Sub: Intimation of Schedule of Analysts / Institutional Investors Meetings by our wholly-owned subsidiary, Jubilant Pharma Limited, Singapore

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and in furtherance of our letter / announcement dated September 23, 2016, we wish to inform you that our material wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore) (“JPL”) proposes to organise meetings with the analysts / institutional investors in connection with the proposed launch of high yield bonds by JPL, outside India. A broad outline of the meetings is given below:

Date of Meetings	Location of Meetings
September 26, 2016	Singapore
September 27, 2016	Hong Kong and London

Details of the meetings will be hosted on the website of Jubilant Life Sciences Limited (the “Company”) (www.jubl.com). The schedule may undergo change due to exigencies on the part of analysts / institutional investors or JPL.

A copy of the investor presentation is also attached herewith and shall also be available on the website of the Company.

The above is for your information and records.

Thanking You,

Yours Sincerely,
For Jubilant Life Sciences Limited



Rajiv Shah
Company Secretary



A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624